We are live on ! Find out more
GWPH

GW Pharmaceuticals Plc American Depositary Shares
GWPH

Delisted

GWPH was delisted on the 4th of May, 2021.

318 hedge funds and large institutions have $4.35B invested in GW Pharmaceuticals Plc American Depositary Shares in 2019 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 107 increasing their positions, 78 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more repeat investments, than reductions

Existing positions increased: 107 | Existing positions reduced: 78

10% more capital invested

Capital invested by funds: $3.94B → $4.35B (+$412M)

6% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 47

1% less funds holding

Funds holding: 320318 (-2)

26% less call options, than puts

Call options by funds: $134M | Put options by funds: $181M

29% less funds holding in top 10

Funds holding in top 10: 75 (-2)

Holders
318
Holders Change
-2
Holders Change %
-0.63%
% of All Funds
6.91%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.11%
New
50
Increased
107
Reduced
78
Closed
47
Calls
$134M
Puts
$181M
Net Calls
-$46.4M
Net Calls Change
+$22.1M
Name Holding Trade Value Shares
Change
Change in
Stake
PCM
251
Prelude Capital Management
New York
$25K -$162K -935 -87%
RFWA
252
RPg Family Wealth Advisory
Massachusetts
$23.4K
FFC
253
First Financial Corp
Indiana
$23K
FDCDDQ
254
Federation des caisses Desjardins du Quebec
Quebec, Canada
$22.2K -$3.81K -22 -15%
KLWA
255
Kelly Lawrence W & Associates
California
$20K +$19.9K +115 New
QT
256
Quantamental Technologies
New York
$20K +$20.2K +117 New
RCM
257
Riverhead Capital Management
Delaware
$19K -$1.38K -8 -7%
AA
258
AlphaMark Advisors
Kentucky
$18K
CFA
259
Carroll Financial Associates
North Carolina
$18K
WEC
260
Winslow Evans & Crocker
Massachusetts
$18K
CAC
261
Certified Advisory Corp
Florida
$17K -$5.19K -30 -24%
TFA
262
Toth Financial Advisory
Virginia
$17K
TFS
263
TrustCore Financial Services
Tennessee
$17K
TNBTD
264
Trustmark National Bank Trust Department
Mississippi
$17K
PMFA
265
Plante Moran Financial Advisors
Michigan
$17K +$5.19K +30 +43%
CFD
266
Creative Financial Designs
Indiana
$16K
NCM
267
Northstar Capital Management
New York
$16K +$7.96K +46 +100%
BDWM
268
Brewin Dolphin Wealth Management
Ireland
$14.3K
MSFP
269
Mark Sheptoff Financial Planning
Connecticut
$14K
S
270
SignatureFD
Georgia
$14K +$13.8K +80 New
SMFS
271
Squar Milner Financial Services
California
$13K
TPWA
272
TRUE Private Wealth Advisors
Oregon
$13K +$13.5K +78 New
HI
273
Hudock Inc
Pennsylvania
$12K
VFA
274
Valeo Financial Advisors
Indiana
$11K -$34.6K -200 -76%
AIM
275
Arcadia Investment Management
Michigan
$11K +$2.59K +15 +30%

GWPH Hedge Fund Activity: Q2 2019 in Review

318 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q2 2019, worth a combined $4.35B — up 10% from $3.94B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new GWPH positions and 47 closed out — a net gain of 3 holders — while 107 added to existing stakes and 78 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $110M. The largest seller was Scopia Capital Management, exiting entirely with an estimated $126M sold.

  • 318 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q2 2019, down from 320 in Q1 2019.
  • Funds reported $4.35B of GW Pharmaceuticals Plc American Depositary Shares stock for Q2 2019, up 10% quarter-over-quarter.
  • 50 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q2 2019 and 47 closed out, a net change of +3 holders.
  • The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q2 2019 was Point72 Asset Management, an estimated $110M added.
  • The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q2 2019 was Scopia Capital Management, an estimated $126M sold.

Based on aggregated 13F filings for Q2 2019.